|Boston Scientific CEO Mike Mahoney|
The deal: Boston Scientific buys Bard's electrophysiology arm
The price tag: $275 million
Why it matters: Simply put, electrophysiology is a rapidly expanding medical device sector, and Boston Scientific ($BSX) scored big last November when it disclosed plans to grab C.R. Bard's ($BCR) electrophysiology arm. On a broader scale, of course, Massachusetts-based Boston Scientific has been on an M&A tear in recent years as it pursues diversification and new business lines to spur a return to robust revenue growth. But electrophysiology represents a strategically smart investment in particular, because of the increased global interest. The deal gives Boston Scientific additional devices in the space focused on cardiac catheter ablations, recording and cardiac mapping, and also therapeutic and diagnostic catheters. Sheer product volume resulting from the acquisition should help spur more aggressive electrophysiology sales for the company in the months ahead. Boston Scientific estimates that the electrophysiology market is already worth $2.5 billion and growing 10% annually.
Boston Scientific closes $275M deal for Bard's electrophysiology arm
Boston Scientific buying Bard's electrophysiology biz for $275M
Boston Sci dives into electrophysiology with $90M Rhythmia buy